| # | Drug | Count |
|---|---|---|
| 0 | PANITUMUMAB | 580 |
| 1 | OXALIPLATIN | 368 |
| 2 | FLUOROURACIL | 357 |
| 3 | FLUOROURACIL CREAM, 0.5% | 357 |
| 4 | AFATINIB | 355 |
| 5 | CAPECITABINE | 305 |
| 6 | CETUXIMAB | 262 |
| 7 | OSIMERTINIB | 225 |
| 8 | BEVACIZUMAB | 184 |
| 9 | TRASTUZUMAB | 182 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) | 10 | 0.0800 |
| 1 | DACOMITINIB | 58 | 0.0777 |
| 2 | LAZERTINIB | 45 | 0.0637 |
| 3 | SELUMETINIB | 87 | 0.0569 |
| 4 | ICHTHAMMOL OINTMENT | 2 | 0.0541 |
| 5 | AFATINIB | 355 | 0.0539 |
| 6 | AMIVANTAMAB-VMJW | 151 | 0.0462 |
| 7 | PEGFILGRASTIM-BMEZ | 25 | 0.0418 |
| 8 | PANITUMUMAB | 580 | 0.0372 |
| 9 | DROPERIDOL | 27 | 0.0167 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 1080 |
| 1 | Epidermal Growth Factor Receptor Antagonist [EPC] | 808 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 667 |
| 3 | Platinum-based Drug [EPC] | 572 |
| 4 | Corticosteroid [EPC] | 432 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 341 |
| 6 | Microtubule Inhibitor [EPC] | 276 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 248 |
| 8 | Tumor Necrosis Factor Blocker [EPC] | 220 |
| 9 | Benzodiazepine [EPC] | 196 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 808 | 0.0175 |
| 1 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 24 | 0.0039 |
| 2 | Dopamine-2 Receptor Antagonist [EPC] | 27 | 0.0036 |
| 3 | Cannabinoid [EPC] | 31 | 0.0031 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 667 | 0.0025 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 186 | 0.0024 |
| 6 | Antiseptic [EPC] | 10 | 0.0023 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 45 | 0.0023 |
| 8 | Kinase Inhibitor [EPC] | 1080 | 0.0022 |
| 9 | Platinum-based Drug [EPC] | 572 | 0.0021 |